The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
The tissue-based test is approved to identify a new classification in HER2 expression designated as HER2-ultralow.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback